Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.

ESMO Open · 2022 · PMC9588894 · PMID 36116421

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

did not reach statistical significanceP = 0.068so close (0.05 < p ≤ 0.1)

No OS benefit was evidenced for the use versus no use of HIPEC at any time point analyzed and despite the fact that some beneficial effect may be argued at the first year of follow-up, this benefit did not reach statistical significance (RR = 0.29; 95% CI 0.08-1.10; P = 0.068).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.